


ALK4290

Cat. No.:	HY-136788		
CAS No.:	1251528-23-0		
Molecular Formula:	C ₂₇ H ₃₄ ClN ₅ O ₃		
Molecular Weight:	512.04		
Target:	CCR		
Pathway:	GPCR/G Protein; Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (97.65 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.9530 mL	9.7649 mL	19.5297 mL
	5 mM	0.3906 mL	1.9530 mL	3.9059 mL
	10 mM	0.1953 mL	0.9765 mL	1.9530 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (4.88 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a K_i of 3.2 nM for hCCR3^[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism^{[2][3]}.

IC₅₀ & Target

CCR3
3.2 nM (K_i)

REFERENCES

- [1]. NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.
- [2]. Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259.
- [3]. Clinical Development of AKST4290 as a Novel Parkinson's Therapeutic
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA